Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Tevogen Bio Holdings Inc. develops off-the-shelf, allogeneic T cell therapies targeting infectious diseases and cancers. Its ExacTcell technology harnesses naturally occurring CD8+ cytotoxic T lymphocytes to create precise, multi-target immune treatments. The company's lead product, TVGN 489, aims to treat COVID-19, Long COVID, and related conditions, offering rapid, scalable, and cost-effective immunotherapies with potential applications across virology and oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.